Germany artificial tears market is estimated to grow considerably at a CAGR of around 4.2% during the forecast period (2024-2031). The market growth is driven by the increasing prevalence of eye surgeries such as cataracts in Germany due to the rising share of the aging population. Additionally, the growing pharmaceutical industry in Germany, owing to increasing investment by the government is creating opportunities for market growth during the forecast period.
Germany artificial tears market is segmented by Type (Cellulose Derived Tears, Glycerin Derived Tears, and Oil-Based Emulsion Tears), by Delivery Method (Artificial Eye Drops and Ointments), by Application (Dry Eyes Treatment, Contact Lenses Moisture, and Others), and by geographies (North America, Europe, Asia-Pacific, and Rest of the World).
Browse the full report description of “Germany Artificial Tears Market Size, Share & Trends Analysis Report by Type (Cellulose Derived Tears, Glycerin Derived Tears, and Oil-Based Emulsion Tears), by Delivery Method (Artificial Eye Drops and Ointments), and by Application (Dry Eyes Treatment, Contact Lenses Moisture, and Others) and Forecast 2024-2031” at https://www.omrglobal.com/industry-reports/germany-artificial-tears
The major players in the Germany artificial tears market include Carl Zeiss Meditec AG, Essilor Group, Novartis International AG, Shire PLC, and Ziemer Ophthalmic Systems AG, among others. The manufacturers in the country are focusing on manufacturing and creating innovative artificial tears that do not contain water, emulsifiers, phosphates, or preservatives, thereby making them more tolerable to the eyes.
Recent Developments
- In September 2024, URSAPHARM expanded its ‘concept for healthy eyelids’, to launch EvoTears® OMEGA eye drops, a comprehensive and coordinated therapeutic approach for the individual treatment and care of lid margin inflammation (blepharitis) and meibomian gland dysfunction. The extended treatment concept includes products for heat treatment, daily lid margin hygiene, and care for the treatment of eyelid diseases. It addresses eyelid diseases such as blepharitis, meibomian gland dysfunction, hordeolum, or chalazion. Dryness, burning, itching, redness, or swelling can be alleviated. The function of the meibomian glands improved and tear film stability increased.
- In August 2023, Novaliq GmbH announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for CyclASol (ciclosporin ophthalmic solution) for regulatory review. It is a new drug treatment for dry eye disease in patients not responding to tear substitutes.
- In July 2023, Novaliq GmbH, hat the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) granted marketing authorization in the European Union for Vevizye®, intended for the treatment of moderate to severe dry eye disease in adult patients, which has not improved despite treatment with tear substitutes.
- In June 2023, Senju Pharmaceutical Co., Ltd., and Novaliq GmbH announced the closing of a license agreement on Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the prescription treatment for signs and symptoms of dry eye disease that directly targets tear evaporation.
- In May 2021, Scope Eyecare and URSAPHARM Arzneimittel GmbH announced a new partnership for the US with the creation and launch of a co-branded range of new and innovative dry eye products for the US dry eye market. The OPTASE® HYLO® co-brand partnership will develop formulations tailored to meet the needs of the US dry eye sufferer across a spectrum of symptom severity.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/germany-artificial-tears